Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Altamira Therapeutics (CYTO)
NASDAQ:CYTO
Holding CYTO?
Track your performance easily
CYTO Stock Chart & Stats
Day’s Range$0.3 - $0.43
52-Week Range― - ―
Previous Close$0.41
Volume830.27K
Average Volume (3M)N/A
Market Cap
$452.67K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Apr 09, 2025EPS Estimate
-$0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,230,000
10 Day Avg. Volume161,187
30 Day Avg. Volume202,905
Standard Deviation0.35
R-Squared0.13
Alpha-0.10
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.15
Price to Sales (P/S)30.00
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Altamira Therapeutics News
PremiumCompany Announcements
Altamira Therapeutics Transitions to OTCQB Following Nasdaq Delisting
PremiumCompany Announcements
Altamira Therapeutics Faces Nasdaq DelistingPremiumCompany Announcements
Altamira Therapeutics Reports Narrowed Losses
Ownership Overview
―
Insiders
0.06% Mutual Funds
2.68% Other Institutional Investors
97.26% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CYTO FAQ
What was Altamira Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Altamira Therapeutics’s market cap?
Currently, no data Available
When is Altamira Therapeutics’s upcoming earnings report date?
Altamira Therapeutics’s upcoming earnings report date is Apr 09, 2025 which is in 108 days.
How were Altamira Therapeutics’s earnings last quarter?
Altamira Therapeutics released its earnings results on Sep 24, 2024. The company reported -$2 earnings per share for the quarter, beating the consensus estimate of -$2.398 by $0.398.
Is Altamira Therapeutics overvalued?
According to Wall Street analysts Altamira Therapeutics’s price is currently Overvalued.
Does Altamira Therapeutics pay dividends?
Altamira Therapeutics does not currently pay dividends.
What is Altamira Therapeutics’s EPS estimate?
Altamira Therapeutics’s EPS estimate is -$0.57.
How many shares outstanding does Altamira Therapeutics have?
Currently, no data Available
What happened to Altamira Therapeutics’s price movement after its last earnings report?
Altamira Therapeutics reported an EPS of -$2 in its last earnings report, beating expectations of -$2.398. Following the earnings report the stock price went up 4.478%.
Which hedge fund is a major shareholder of Altamira Therapeutics?
Currently, no hedge funds are holding shares in CYTO
---
Altamira Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.36%
Trailing 12-Months
Company Description
Altamira Therapeutics
Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertigo and for the prevention of antipsychotic-induced weight gain and somnolence. It also includes other programs under development such as Keyzilen, for the treatment of acute inner ear tinnitus; and Sonsuvi, for the treatment of acute inner ear hearing loss. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.
---
CYTO Earnings Call
Q2 2024
0:00 / 0:00
---
Technical Analysis
---